NAGHAHANDA na ang pharmaceutical industry para sa worst-case scenario sa harap ng pangamba sa global medicine shortage ng mga bansa na tinamaan ng coronavirus
Ito ay makaraang ianunsiyo ng India, ang pangunahing supplier ng generic drugs sa mundo, ang paghihigpit sa export ng dose-dosenang common medicine sa gitna ng mabilis na pagkalat ng COVID-19.
“Because our companies have different scenarios built into their operations, they have contingencies so that in case a supplier cannot come in, they have supplies from other parts of the world, other regions which will hopefully not also be affected by this virus,” pahayag ni Teodoro Padilla, executive director ng Pharmaceutical and Healthcare Association of the Philippines, sa CNN Philippines’ The Source kahapon.
Sa kaagahan ng buwan ay binawasan ng Indian Ministry of Commerce and Industry ang export ng 26 medicinal products, kabilang ang widely-used pain reliever Paracetamol.
“Exports of specified APIs (Active Pharmaceutical Ingredients) and formulations made from these APIs under the ITC HS Codes mentioned against each is hereby ‘restricted’, with immediate effect and till further orders,” nakasaad sa kautusan ng Commerce Department ng India na may petsang Marso 3.
Ayon kay Padilla, ang mga merkado na umaasa ng stocks mula sa India at China, kung saan nagsimula ang COVID outbreak at kinukuha ng India ang karamihan sa kanilang mga sangkap, ay maaaring maharap sa drug supply constraints dahil sa global situation.
“Those who are dependent on a single source— whether it’s China, whether it’s India, will have some supply constraints coming up… Many of the products made in India use active pharmaceutical ingredients coming from China, which is like the supplier of the world in many aspects,” ayon sa opisyal.
Mino-monitor ng international markets, kabilang ang United States Food and Drug Administration, ang pharmaceutical supply chain para sa posibleng kakulangan, dahil ilang bahagi ng China ang naka-lockdown dahil sa outbreak.